by University of Luxembourg An international collaboration involving researchers from the Luxembourg Center for Systems Biology (LCSB) at the University of Luxembourg established an association between inflammation and specific genetic mutations in Parkinson’s patients. The study, recently published in the scientific journal Brain, highlights two biomarkers that could be used to assess Parkinson’s disease state and progression. The results...
by American Academy of Neurology Even for people with a gene mutation tied to Parkinson’s disease, coffee consumption may be associated with a lower risk of actually developing the disease, according to a new study published in the September 30, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology. “These results are...
AARHUS UNIVERSITY Although the name may suggest otherwise, Parkinson’s disease is not one but two diseases, starting either in the brain or in the intestines. Which explains why patients with Parkinson’s describe widely differing symptoms, and points towards personalized medicine as the way forward for people with Parkinson’s disease. This is the conclusion of a...
By Gunjan Sinha Light therapy can help lift moods, heal wounds, and boost the immune system. Can it improve symptoms of Parkinson’s disease, too? A first-of-its-kind trial scheduled to launch this fall in France aims to find out. In seven patients, a fiber optic cable implanted in their brain will deliver pulses of near-infrared (NIR) light...
by University of Luxembourg Microscopy pictures of neurons derived from skin cells. Credit: University of Luxembourg In a seven-year research effort, an international team of scientists has clarified the cause for certain genetic forms of Parkinson’s disease, and has identified potential pharmacological treatments. The interdisciplinary research team, led by Prof. Rejko Krüger, of the Luxembourg Centre...
VIB (THE FLANDERS INSTITUTE FOR BIOTECHNOLOGY) Screening DNA of Parkinson’s patients in the Christine Van Broeckhoven laboratory (VIB-UAntwerpen Center for Molecular Neurology) identified a new risk gene for Parkinson’s disease. Mutations in ATP10B resulted in loss of ATP10B protein. The function of the ATP10B gene was revealed by the Peter Vangheluwe lab (KU Leuven, Laboratory...
by American College of Physicians Long-term treatment with immediate-release isradipine does not seem to slow the clinical progression of early-stage Parkinson’s disease. Findings from a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial are published in Annals of Internal Medicine. Despite multiple prior studies, there are no proven strategies for slowing the progression of Parkinson’s disease. Isradipine,...
People with Parkinson’s disease who engage in cognitive behavioral therapy are more likely to overcome depression and anxiety, according to a new study. Cognitive behavioral therapy is a form of psychotherapy that increases awareness of negative thinking and teaches coping skills. About 50% of people diagnosed with Parkinson’s disease will experience depression, and up to...
by University of Leeds A master control region of a protein linked to Parkinson’s disease has been identified for the first time. The finding, made by scientists from the University of Leeds’ Astbury Centre for Structural Molecular Biology, provides a new target for the development of therapies to try and slow down or even prevent...
by University of Georgia Researchers at the University of Georgia’s Regenerative Bioscience Center and their colleagues have found that “natural killer” white blood cells could guard against the cascade of cellular changes that lead to Parkinson’s disease and help stop its progression. Natural killer (NK) cells are white blood cells that can kill tumors without...
